Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
People who received semaglutide injections during clinical trials achieved a 5.9% weight loss percentage at 3 months and 10.9% at 6 months.* After 6 months, there were reports of individuals with higher BMIs (body mass index) losing 20-30% of their body weight
Orforglipron is the first oral non-peptide GLP-1 receptor agonist in development for FDA approval to treat weight loss, which could make it more convenient than injectable alternatives 1
1 Lamotrigine A case series presented at the American Epilepsy Society reported two cases of lamotrigine toxicity following the initiation of GLP-1 receptor agonists
This makes sure you stay safe and get the right results when working on weight loss or blood sugar control
